Irifrin - instructions for use, reviews, analogs and forms of release (eye drops 2.5% and 10% in solution) of the drug for the treatment of iridocyclitis and dilated pupil in adults, children and during pregnancy

In this article, you can read the instructions for using the drug Irifrin. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Irifrin in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Irifrin with available structural analogues. Use for the treatment of iridocyclitis and dilated pupil in adults, children, as well as during pregnancy and lactation.

Irifrin - sympathomimetic. Has a pronounced alpha-adrenergic activity and when used in usual doses does not have a significant stimulating effect on the central nervous system.

With topical application in ophthalmology causes the dilatation of the pupil, improves the outflow of intraocular fluid and narrows the vessels of the conjunctiva.

Phenylephrine (the active substance of the preparation Irifrin) has a pronounced stimulating effect on postsynaptic alpha-adrenoreceptors, has very little effect on myocardial beta-adrenoceptors. The drug has a vasoconstrictive action, similar to the action of norepinephrine (noradrenaline), while it has virtually no chronotropic and inotropic effect on the heart. The vasopressor effect of phenylephrine is less pronounced than that of norepinephrine, but is more prolonged. Causes vasoconstriction after 30-90 seconds after instillation, the duration of action is 2-6 hours.

After instillation, phenylephrine reduces the pupil dilator and smooth muscle of the arterioles of the conjunctiva, thereby causing a dilated pupil. Midriaz occurs within 10-60 minutes after a single instillation.After instillation of eye drops 2.5% of mydriasis is retained for 2 hours, after instillation of eye drops 10% - 3-7 hours. Since phenylephrine has little effect on the ciliary muscle, mydriasis occurs without cycloplegia.

Composition

Phenylephrine hydrochloride + excipients.

Indications

• iridocyclitis (to prevent the occurrence of posterior synechia and to reduce exudation from the iris);
• for diagnostic dilatation of the pupil in ophthalmoscopy and other diagnostic procedures necessary for monitoring the state of the posterior segment of the eye;
• conducting a provocative test in patients with a narrow angle of the anterior chamber of the eye and suspected of a closed-angle glaucoma;
• differential diagnosis of superficial and deep injection of the eyeball;
• in ophthalmic surgery - with preoperative preparation for the dilatation of the pupil (eye drops 10%);
• for the dilatation of the pupil during laser interventions on the fundus and in vitreo-retinal surgery;
• treatment of glaucoma-cyclical crises;
• treatment of the syndrome of "red eye" (eye drops 2.5%) to reduce hyperemia and irritation of the membranes of the eye;
• spasm of accommodation.

Forms of release

Eye drops 2.5% and 10%.

Eye drops 2.5% Irifrin BK.

Instructions for use and how to use them

When conducting ophthalmoscopy, ocular drops 2.5% are applied once in the form of instillations. As a rule, for the creation of mydriasis, it is sufficient to introduce 1 drop into the conjunctival sac. The maximum mydriasis is reached after 15-30 minutes and remains at a sufficient level for 1-3 hours. If it is necessary to maintain mydriasis for a long time after 1 hour, it is possible to re-instill Irifrin.

In adults and children older than 12 years with insufficient expansion of the pupil, as well as in patients with rigid iris (pronounced pigmentation), a 10% drop of eye can be administered at the same dose for diagnostic dilatation of the pupil.

To remove the spasm of accommodation, adults and children over 6 years of age are prescribed eye drops 2.5% 1 drop per eye per night daily for 4 weeks.

In the case of a persistent accommodation spasm, eye drops of 10% in adults and children over 12 years of age can be administered - 1 drop in each eye at night every day for 2 weeks.

When performing diagnostic procedures, single instillation of eye drops 2.5% is used in the following cases:

• as a provocative test in patients with a narrow anterior chamber angle profile and suspicion of occlusive glaucoma - if the difference between intraocular pressure values ​​prior to instillation of Irifrin and after dilated pupil is 3 to 5 mm Hg, then the provocation test is considered positive;
• for differential diagnosis of the type of injection of the eyeball - if 5 min after instillation there is a narrowing of the vessels of the eyeball, the injection is classified as superficial, while maintaining the redness of the eye, it is necessary to carefully examine the patient for the presence of iridocyclitis or scleritis. this indicates the expansion of the more deep-seated vessels.

Iridriklitah Irifrin used in the form of drops of the eye 2.5% or 10% to prevent the development and rupture of the already formed rear synechia and to reduce exudation in the anterior chamber of the eye. For this purpose, a drop of the patient's eye (eye) in the conjunctival sac of 1 drop 2-3 times a day.

In glaucoma-cyclical crises, due to the vasoconstrictive effect of phenylephrine, the intraocular pressure decreases, this effect is more pronounced when using Irifrin in the form of drops of ocular 10%.To stop glaucoma-cyclical crises, the drug is instilled 2-3 times a day.

In preparation for surgical procedures for 30-60 minutes prior to surgery to achieve produced mydriasis Irifrin single instillation of eye drops in the form of 10%. After opening the shells of the eyeball, repeated instillation of the drug is not allowed.

Eye drops 10% are not used for irrigation, impregnation of tampons during surgery and for subconjunctival administration.

Side effect

• conjunctivitis;
• periorbital edema;
• burning sensation at the beginning of the application;
• blurred vision;
• irritation, discomfort;
• lacrimation;
• increased intraocular pressure;
• reactive miosis;
• a feeling of palpitations;
• tachycardia;
• arrhythmia (including ventricular);
• arterial hypertension;
• reflex bradycardia;
• occlusion of the coronary arteries;
• pulmonary embolism;
• contact dermatitis;
• myocardial infarction;
• vascular collapse;
• intracranial hemorrhage.

Contraindications

• narrow-angle or narrow-angle glaucoma;
• patients of advanced age with serious disorders from the cardiovascular system and cerebral circulation;
• for additional dilatation of the pupil during surgical operations in patients with a violation of the integrity of the eyeball, as well as in violation of tear production;
• aneurysm of arteries (eye drops 10%);
• hyperthyroidism;
• hepatic porphyria;
• congenital deficiency of glucose-6-phosphate dehydrogenase;
• children's age to 12 years (eye drops 10%);
• premature (eye drops 2.5%);
• hypersensitivity to the drug.

Application in pregnancy and lactation

Since the effect of Irifrin during pregnancy and lactation is not well understood, the use of the drug in these patients is only possible if the expected benefit of therapy for the mother exceeds the potential risk to the fetus or infant.

special instructions

Precautions should be taken with Irifrin in patients with diabetes because of the risk of developing a blood pressure associated with a violation of autonomic regulation, as well as in elderly patients - because of the increased risk of reactive miosis.

Caution should be applied to Irifrin simultaneously with MAO inhibitors, and also within 21 days after discontinuation of their administration.

Exceeding the recommended dose when using eye drops 2.5% in patients with trauma, eye disease or its appendages, in the postoperative period or with reduced tear production (anesthesia) can lead to an increase in the absorption of phenylephrine and the development of systemic side effects.

Due to the fact that the drug causes hypoxia of the conjunctiva, it should be used with caution in patients with sickle cell anemia, with contact lenses, after surgical interventions (reduction of healing).

Drug Interactions

The mydriatic effect of phenylephrine is enhanced when it is used in combination with atropine. Because of the increased vasopressor effect, tachycardia can develop.

When applying Irifrin simultaneously with MAO inhibitors or within 21 days after discontinuation of their intake, there is a risk of developing uncontrolled rise in blood pressure.

The vasopressor effect of adrenomimetic agents can also be potentiated when combined with tricyclic antidepressants, propranolol, reserpine, guanethidine, methyldopa, and m-holinoblokatorami.

The use of Irifrin in the form of drops of ocular 10% in combination with systemic application of beta-blockers can lead to acute hypertension.

Irifrin can potentiate a depressing effect on the activity of the cardiovascular system with inhalation anesthesia.

Application in conjunction with sympathomimetics can enhance the cardiovascular effects of phenylephrine.

Analogues of the drug Irifrin

Structural analogs for the active substance:

• Visophrine;
• Irifrin BC;
• Mesatone;
• Nazol Baby;
• Nazole Kids;
• Neosinephrine PIC;
• Phenylephrine hydrochloride.

Similar medicines:

Other medicines: